Panatrix (Ceftriaxone)

Ceftriaxone, the active ingredient in Panatrix, is a cephalosporin presented as a strength/form for intravenous use. It treats a broad range of bacterial infections in adults and children. GNH USA supplies Panatrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Panatrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Ceftriaxone is a broad‑spectrum antibiotic that acts on Gram‑negative and Gram‑positive bacteria in several clinical contexts.

- Community‑acquired pneumonia: helps eradicate the causative bacterial pathogens and improve respiratory symptoms. - Uncomplicated urinary tract infection: eliminates the infecting organism and resolves urinary symptoms. - Gonorrhoea: provides a single‑dose cure by targeting Neisseria gonorrhoeae. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat the infection and reduce inflammation. - Skin and soft‑tissue infections: clears the bacterial cause and promotes wound healing.

Ceftriaxone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Diarrhea: mild to moderate watery stools. - Nausea: occasional upset stomach. - Injection site pain: local discomfort after IV administration. - Rash: transient skin erythema. - Elevated liver enzymes: mild, transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption. - Hemolytic anemia: immune‑mediated destruction of red blood cells. - Stevens‑Johnson syndrome: extensive skin detachment and mucosal involvement. - Renal impairment: worsening kidney function in susceptible patients.

Ceftriaxone should be used with careful clinical assessment and monitoring.

- Renal impairment: adjust or monitor dosing in patients with reduced kidney function. - Hepatic dysfunction: use cautiously in patients with liver disease. - Biliary sludge/gallstones: monitor patients with prolonged therapy. - Neonates and infants <28 days: avoid due to risk of bilirubin displacement. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Ceftriaxone can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Calcium‑containing solutions: risk      ...

Moderate  ...